Sanofi, BEYFORTUS
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.
Sanofi received FDA approval for a new manufacturing line to expand production of Beyfortus, a preventive therapy for respiratory syncytial virus in infants. Beyfortus is the first long-acting ...
The new, free vaccine, Beyfortus, will be available to children up to 24 months old through their health care provider or at ...
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback